71 / 100

YOON-JUNG CHOI | Bacteriophage Therapy | Research Excellence Distinction Award

Department of Biomedical Sciences | The Graduate School Kyungpook National University | South Korea

🌟 Yoon-Jung Choi is a distinguished microbiologist from Daegu, Republic of Korea. With extensive experience in microbiology and food science, Yoon-Jung is currently a postdoctoral researcher at Kyungpook National University’s School of Medicine.

Profile

ORCID

Education

  • Postdoctoral Researcher in Microbiology (Mar 2024 – Present), Department of Microbiology, School of Medicine, Kyungpook National University, Daegu, Republic of Korea.
  • Ph.D. in Microbiology (Mar 2020 – Feb 2024), Department of Microbiology, School of Biomedical Science, Kyungpook National University, Daegu, Republic of Korea.
    • Thesis: “Bacteriophage-Based Approaches to Combat Acinetobacter baumannii Infections.”
  • M.S. in Food Microbiology (Mar 2010 – Feb 2012), School of Food Science and Biotechnology, Kyungpook National University, Daegu, Republic of Korea.
  • B.S. in Food Engineering and Food and Nutrition (Mar 2006 – Feb 2010), School of Food Science and Biotechnology, Daegu National University, Daegu, Republic of Korea.

Experience

  • Researcher at NiKom (Apr 2019 – Nov 2019), Gyeongbuk Agricultural Research and Extension Services (Oct 2018 – Mar 2019), Cosmetic Molecular Cell Biology Laboratory (Dec 2017 – May 2018), Gyeongbuk Agricultural Research and Extension Services (Aug 2014 – Dec 2015), MEDIOGEN CO. (Dec 2011 – Apr 2014).

Research Interests

  • Bacteriophage therapy and antimicrobial peptides.
  • Antibiotic resistance mechanisms in clinical pathogens.
  • Fermentation technology and food microbiology.
  • Detection methods for pathogenic bacteria using phage endolysins.

Awards

  • Best Poster Award in Chemistry & Food Science Session, Shizuoka University Japan (2011).

Publications

  1. 2024CHAPSAP26-161, a truncated protein and enzymatic active domain of endolysin LysSAP26, as a potential therapeutic agent to combat Clostridioides difficile infection. Journal of Bacteriology and Virology. Cited by: 10 articles
  2. 2024A novel truncated CHAP modular endolysin, CHAPSAP26-161, that lyses Staphylococcus aureus, Acinetobacter baumannii, and Clostridioides difficile, and exhibits therapeutic effects in a mouse model of Acinetobacter baumannii infection. Journal of Microbiol Biotechnol. Cited by: 15 articles
  3. 2023Development of a Magnetic Bead-Based Method for Specific Detection of Enterococcus faecalis Using C-Terminal Domain of ECP3 Phage Endolysin. Journal of Microbiol Biotechnol. Cited by: 8 articles
  4. 2023Differentiation of Escherichia fergusonii and Escherichia coli Isolated from Patients with Inflammatory Bowel Disease/Ischemic Colitis and Their Antimicrobial Susceptibility Patterns. Antibiotics. Cited by: 12 articles
  5. 2021Antibacterial Effects of Recombinant Endolysins in Disinfecting Medical Equipment: A Pilot Study. Frontiers in Microbiology. Cited by: 20 articles
  6. 2020LysSAP26, a New Recombinant Phage Endolysin with a Broad Spectrum Antibacterial Activity. Viruses. Cited by: 25 articles

 

 

YOON-JUNG CHOI | Bacteriophage Therapy | Research Excellence Distinction Award

You May Also Like